deferoxamine has been researched along with Hepatitis C, Chronic in 6 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Hepatitis C, Chronic: INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although IFN therapy is known to cause neutropenia, data on the risk of deferiprone (DFP)-induced haematological complications in patients receiving IFN are lacking." | 7.76 | The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study. ( Ammirabile, M; Cinque, P; Costantini, S; Di Costanzo, G; Di Matola, T; Lanza, AG; Pagano, L; Prossomariti, L; Ricchi, P; Spasiano, A, 2010) |
| "Deferiprone (L1) was found to have greater efficacy at depleting myocardial iron than desferrioxamine (DFX)." | 5.32 | Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. ( Chang, JS; Peng, CT; Tsai, CH; Wu, KH, 2004) |
| "Although IFN therapy is known to cause neutropenia, data on the risk of deferiprone (DFP)-induced haematological complications in patients receiving IFN are lacking." | 3.76 | The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study. ( Ammirabile, M; Cinque, P; Costantini, S; Di Costanzo, G; Di Matola, T; Lanza, AG; Pagano, L; Prossomariti, L; Ricchi, P; Spasiano, A, 2010) |
| "Deferiprone (L1) was found to have greater efficacy at depleting myocardial iron than desferrioxamine (DFX)." | 1.32 | Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. ( Chang, JS; Peng, CT; Tsai, CH; Wu, KH, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biliotti, E | 1 |
| Palazzo, D | 1 |
| Serani, M | 1 |
| Silvestri, AM | 1 |
| Volpicelli, L | 1 |
| Esvan, R | 1 |
| Franchi, C | 1 |
| Spaziante, M | 1 |
| Sorrentino, F | 1 |
| Taliani, G | 1 |
| Mahmoud, A | 1 |
| Musallam, KM | 1 |
| Taher, AT | 1 |
| Yap, J | 1 |
| O'Connor, C | 1 |
| Kirby, M | 1 |
| Guindi, M | 1 |
| Roberts, EA | 1 |
| Fragatou, S | 1 |
| Tsourveloudis, I | 1 |
| Manesis, G | 1 |
| Ricchi, P | 1 |
| Ammirabile, M | 1 |
| Costantini, S | 1 |
| Cinque, P | 1 |
| Lanza, AG | 1 |
| Spasiano, A | 1 |
| Di Matola, T | 1 |
| Di Costanzo, G | 1 |
| Pagano, L | 1 |
| Prossomariti, L | 1 |
| Wu, KH | 1 |
| Chang, JS | 1 |
| Tsai, CH | 1 |
| Peng, CT | 1 |
6 other studies available for deferoxamine and Hepatitis C, Chronic
| Article | Year |
|---|---|
Interferon free antiviral treatment of chronic hepatitis C in patients affected by β-thalassemia major.
Topics: Adult; Antiviral Agents; Benzimidazoles; Benzoates; beta-Thalassemia; Cryoglobulinemia; Deferasirox; | 2017 |
Iron and hepatitis C: what can we learn from thalassemia major?
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferoxamine; Female; Ferritins; | 2008 |
Sequential antiviral and iron chelation treatment in a teenage boy with congenital anemia, chronic hepatitis C, and secondary hemosiderosis.
Topics: Adolescent; Anemia; Antiviral Agents; Chelation Therapy; Deferoxamine; Ferritins; Hemoglobinopathies | 2009 |
Incidence of hepatocellular carcinoma in a thalassemia unit.
Topics: Adult; Aged; Antibodies; Carcinoma, Hepatocellular; Chelation Therapy; Deferoxamine; Female; Hepatit | 2010 |
The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study.
Topics: Adult; Agranulocytosis; Antiviral Agents; beta-Thalassemia; Deferiprone; Deferoxamine; Drug Therapy, | 2010 |
Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
Topics: Adult; beta-Thalassemia; Cardiovascular Agents; Deferiprone; Deferoxamine; Diabetes Complications; D | 2004 |